期刊文献+

N-乙酰半胱氨酸防治老年患者化疗药物性肝肾损害的临床研究 被引量:1

Clinical research of N-acetylcysteine in alleviating hepatorenal damage caused by chemotherapeutic drugs in elderly patients
原文传递
导出
摘要 目的探讨N-乙酰半胱氨酸(NAC)注射液对老年患者以顺铂为主的联合化疗所导致肝肾损害的改善作用。方法40例接受肿瘤化疗的老年患者随机自身交叉分为AB和BA组,AB组第1周期为化疗加NAC治疗10d,第2周期为化疗加肌苷、维生素C注射液10d;BA组第1周期为化疗加肌苷、维生素C注射液治疗10d,第2周期为化疗加NAC治疗10d,每21天为1个周期。观察比较两组患者肝肾损害程度的差异,并评价NAC治疗肝肾损害的疗效。结果A周期化疗后血清丙氨酸氨基转移酶(ALT)水平(29.18±5.43)U/L、门冬氨酸氨基转移酶(AST)水平(32.37±7.13)U/L、肌酐(95.22±20.60)/μmol/L,与化疗前[分别为(25.32±5.23)U/L、(29.21±6.51)U/L和(89.87±19.56)μmol/L]比较,差异均无统计学意义(均为P〉0.05);B周期化疗后ALT(56.76±5.53)U/L、AST(48.83±6.64)U/L和肌酐(137.33±21.16)μmol/L,较化疗前[分别为(26.19±5.51)U/L,(29.95±6.56)U/L和(88.66±18.27)μmol/L]均增高(均为P〈0.01)。结论NAC对老年患者化疗所致肝肾功能损害有明昂保护作用,可防治化疗所砷的肝肾功能损害. Objective To evaluate the effect of N-acetylcysteine (NAC) on alleviating hepatorenal damage caused by combined chemotherapy using cisplatin-based regiments in elderly patients. Methods All 40 elderly patients with malignant tumors were randomly divided into AB and BA group in cross-over pattern. In AB group, combination of chemotherapy and NAC was administrated for 10 days first, and then combination of chemotherapy, earnine and vitamin C was given for 10 days. In BA group, combination of chemotherapy, carnine and vitamin C was administrated for 10 days first, and then combination of chemotherapy and NAC was given for 10 days, a cycle was 21 days. The hepatorenal damage degree was observed and the curative effect of NAC on hepatorenal damage was evaluated. Results There were no differences in the levels of alanine aminotransferase(ALT), aspartate aminotransferase(AST) and serum creatinine(Cr) between pre chemotherapy and post chemotherapy in A cycle [(25. 32±5. 23) U/L vs. (29. 18±5.43) U/L, (29. 21±6. 51)U/L vs. (32.37±7. 13 )U/L, (89.87±9.56)μmol/L vs. (95.22±20.60)μmol/L, all P〉0. 05]. In B cycle, the levels of ALT,AST and Cr were (56. 76±5.53) U/L, (48.83±6.64) U/L and ( 137.33 ±21.16)μmol/L post chemotherapy, respectively, which were evidently higher than pre chemotherapy [( 26. 19 ± 5.51 ) U/L, ( 29.95 ± 6.56 ) U/L and ( 88.66 ± 18.27 ) μmol/L, respectively]( all P〈0.01) . Conclusions NAC has better preventive and therapeutic effects on hepatorenal damage caused by the chemotherapeutic drugs in elderly patients with malignant cancer.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2009年第8期668-670,共3页 Chinese Journal of Geriatrics
关键词 乙酰半胱氨酸 药物疗法 联合 肝功能不全 肾功能不全 Acetylcysteine Drug therapy, combination Hepatic insufficiency Renalinsufficiency
  • 相关文献

参考文献10

二级参考文献39

  • 1Yang CT,You L,Yeh CC, et al. Adenovirus-mediated pl4ARF(ARF)gene transfer in human mesothelioma cells. J Natl Cancer Inst, 2000,92 : 636-641.
  • 2Esteller M, Tortola S, Toyota M, et al.Hypermethylation-associat ed inactivation or p14ARF(ARF) is independent of p16(1NK4a) methylation and p53 mutational status. Cancer Res, 2000,60 : 129-133.
  • 3Fader S.Estrov Z, Kantarjian HM, et al.The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes P15 ( 1NK4b/p16 ( 1NK4a )/p14ARF(ARF) in patients with acute lymphoblastic leukemia. Cytokines Cell Mol Ther, 1999.5 : 159-163.
  • 4Francis PA, Rigas JR, Kris MG, et al. Phase Ⅱ trial of docetaxel in patients in with stage Ⅲ and Ⅳ non-small cell lung cancer. J Clin Oncol,1994, 12: 1232-1237.
  • 5Hainsworth JD,Burris Ⅲ HA, Greco FA. Weekly Administration of Docetaxel (Taxotere): summary of clinical data. Semin Oncol,1999,26( Suppl 10) : 19-24.
  • 6Fossella FV, Lee JS, Murphy WK, et al. Phase Ⅱ study of docetaxel for recurrent or metastatic non small cell lung cancer. J Clin 0ncol, 1994, 12: 1238-1244.
  • 7Fossella FV, Lee JS, Berilh J, et al. Summary of phase Ⅱ data of docetaxel(Taxotere), an active agent in the first and second line treatment of advanced non small cell lung cancer. Semin Oneol,1995, 22(2 Suppl 4) :22-29.
  • 8Belani CP. Single agents in the second line treatment of non small cell lung cancer. Semin 0neol,1998, 25(3 Suppl 8) : 10-14.
  • 9Ravdin PM, Bun'is HA, Cook G, et al. Phase Ⅱ trial of docetaxel inadvanced anthracicline-resistant or anthracenedione-resistant breast cancer. J Clin 0ncol,1995, 13:2879-2885.
  • 10Kubota K, Watanabe K, Kunitoh H,et al. Phase Ⅲ randomized trial of decetaxel plus cisplatin versus vindesine plus cispaltin in patients with stage Ⅳ non small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol, 2004, 22:354-261.

共引文献33

同被引文献30

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部